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Abbreviations 
 
 
AHA  azidohomoalanine 
CSC  cancer stem cell 
DAPI  4',6-diamino-2-phenylindole 
DTT  dithiothreitol 
ECM  extracellular matrix 
GBM  glioblastoma multiforme 
GNS  glioblastoma-derived neural stem cells 
GO   gene ontology 
GSEA  gene seat enrichment analysis 
IAA  iodoacetamide 
IEF  isoelectric focusing 
NPC  neural progenitor cells 
NS  neural stem cell 
pSILAC pulsed SILAC 
SILAC  stable isotope labeling with amino acids in cell culture 
TF  transcription factor 
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Summary 
 
Glioblastoma multiforme (GBM) (grade IV astrocytoma) is the most common and aggressive 
primary brain tumour. GBM consists of heterogeneous cell types includinga subset of stem cell-like 
cells thought to sustain tumour growth. These tumour-initiating GBM-derived neural stem (GNS) 
cells as well as their genetically normal neural stem (NS) counterparts can be propagated in 
culture as relatively pure populations. Here we perform quantitative proteomics to globally 
characterize and compare total proteome plus the secreted proteome (secretome) between GNS 
cells and NS cells. Proteins and pathways that distinguish malignant cancer (GNS) stem cells from 
their genetically normal counterparts (NS cells) might have value as new biomarkers or therapeutic 
targets. Our analysis identified and quantified ~7500 proteins in the proteome and ~2000 in the 
secretome, 447 and 138 of which were differentially expressed, respectively. Notable tumour-
associated processes identified using gene set enrichment analysis included: ECM interactions, 
focal adhesion, cell motility and cell signalling. We focused on differentially expressed surface 
proteins, and identified 26 that participate in ligand-receptor pairs that play a prominent role in 
tumourigenesis. Immunocytochemistry and immunoblotting confirmed that CD9, a recently 
identified marker of adult subventricular zone neural stem cells, was consistently enriched across a 
larger set of primary GNS cell lines. CD9 may therefore have value as a GNS-specific surface 
marker and a candidate therapeutic target.  Altogether, these findings support the notion that 
increased cell-matrix and cell-cell adhesion molecules play a crucial role in promoting the tumour 
initiating and infiltrative properties of GNS cells. 
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Significance 
Glioblastoma multiforme is the most aggressive primary brain tumour, sustained by tumour-
initiating glioblastoma-derived neural stem cells. We performed proteomics to identify the 
molecular signatures that distinguish malignant cancer stem cells from normal neural stem cells, 
i.e. their non-neoplastic counterparts. By quantitative profiling of the proteins that are expressed 
and secreted by both cell types across a wide range of patient-derived primary cell lines, we 
revealed elevated expression of many cell-matrix and cell-cell adhesion proteins in glioblastoma 
stem cells. In addition, we demonstrated consistently higher expression of the cell surface protein 
CD9 in glioblastoma stem cells indicating this may have a functional role in conferring GNS specific 
infiltrative properties, and could also prove useful as a surface marker.  
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Introduction 
 
Among primary adult brain tumours, glioblastoma multiforme (GBM), also termed grade IV 
astrocytoma, is the most common and severe form, with a median survival time of only 15 months 
[1]. GBMs can be initiated in xenograft models following transplantation into immuno-compromised 
mice of a subpopulation of neural stem cell-like cells derived from patient samples. Such cells are 
critical therapeutic targets as they likely fuel tumour growth and relapse after therapy [2-4] . GBM 
stem cell-like cells exhibit functional properties that are shared with normal neural stem cells, such 
as self-renewal and ability to differentiate. For this reason, tumour-derived stem cell-like cells are 
commonly referred to as CSCs, or tumour-initiating cells. 
Efforts have been made to catalogue genetic aberrations in GBM and associated disrupted 
signalling pathways [5-7]. However, individual tumours are comprised of varying proportions of 
immature CSCs and their more differentiated progeny, as well as genetically normal cells (e.g. 
microglia, tumour-associated macrophages and lymphocytes). Elucidating genes and pathways 
that drive tumour cell malignancy using genetic and biochemical approaches in bulk tumour cell 
populations can be misleading, as only an average of molecular signatures can be obtained. It is 
therefore important to explore glioma pathways specifically within the GBM stem cell compartment. 
 Ideally, one would compare the genetically normal tissue stem cell with its malignant 
counterpart under identical experimental conditions. Tumour-specific pathways might then be 
identified that underlie vulnerabilities that could be targeted therapeutically [8] . ‘Classic’ glioma cell 
lines fail to provide a realistic disease model, largely due to accumulation of in vitro genetic 
changes to adapt to the serum culture environment [9] . By contrast, serum-free NS cell culture 
conditions can be used successfully to enrich and expand brain tumour stem cells either in 
suspension as ‘spheres’ [2, 4, 10-12] or using adherent monolayer NS cell-culture conditions; the 
latter providing a more uniform culture environment that suppresses spontaneous differentiation 
[3]. Karyotypically normal, untransformed foetal NS cells share many features with GNS cells, such 
as expression of key neural stem/progenitor markers and core transcription factors, such as 
NESTIN, OLIG2 and SOX2 [3]. 
Here we search for molecular signatures differentially utilized by the malignant GNS cells 
compared to genetically normal NS cells. Quantitative proteomics was performed using our 
recently developed technique for secretome analysis [13] . This significantly extends and refines a 
previous study that used neurosphere cultures and 2D-gel-based proteomic technologies [14] , and 
provides a valuable proteomics resource for future glioma studies. We identified GNS-specific 
signatures, such as differentially expressed secreted proteins, plasma membrane receptors, 
transcription factors (TFs) and deregulated signalling pathways, which representcandidate 
biomarkers and therapeutic targets. CD9 emerges from our study as a useful cell surface marker 
consistently highly expressed in GNS cells compared to NS cells. CD9 has previously been 
defined as a regulator of cancer cell motility, and recently shown to be a marker of quiescent 
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astrocyte stem cells in mice [15]. 
 
 
Materials and methods 
 
Cell lines 
For the total cell proteome analysis, NS cell lines (CB660, CB192, CB152 and CTX985) were 
derived from human foetal forebrain (between weeks 7 and 9). GNS lines included (G144, G166, 
G179 and G25 and cover a diversity of primary GBM subtypes with transcriptional signatures 
across proneural and mesenchymal phenotypes [16]. Tissues were obtained following informed 
consent and approval of ethical review panels (reference number 08/H0712/34+5). Full details of 
NS and GNS cell line derivation and propagation is described elsewhere [3, 17]. For the secretome 
experiment, CB660, U5 and CB11130 NS cell lines, and G179, G144 and G7 GNS cell lines were 
used; U5 was used instead of CTX985 as it grew better as a monolayer. The cell lines CB660, 
CB152, G166, G7 are female, whereas CB11130, G144, G179 are male. Gender of U3 and U5 is 
not known. 
 
Cell culture 
Both NS cells and GNS cells were cultured serum-freein Dulbecco's modified Eagle's medium 
supplemented with bovine serum albumin (Invitrogen), penicillin/streptomycin (PAA), N2 
supplement (PAA), B27 supplement (PAA), EGF (Peprotech), FGF (Peprotech) and laminin 
(Sigma), as described previously [3, 18] . Culture medium was replaced every 3–5 days. Cells 
were grown to 60-70 % confluence (2 – 4 million cells), harvested and split 1:3 to 1:4. The passage 
numbers used for our analysis were p20 for CB660, p27 for CB192, p15 for CB152, p10 for 
CTX985, p28 for G144, p18 for G166, p18 for G179 and p26 for G25. Our previous studies have 
noted a risk of in vitro chromosomal aberrations after passage 20 [3]; however, these are mainly 
whole chromosome gains and losses (i.e. chromosome instability), which is a feature of the 
disease. Here, we reduce the risk of genetic drift by using multiple cell lines across patient 
subtypes. Secretome analysis was performed combining enrichment of secreted proteins via click 
chemistry and SILAC labelling [13, 19]. For stable isotope-labelled amino acid labelling (SILAC) 
and AHA-labelling for the secretome analysis, cells were grown to 60-70% confluence. Then, the 
cells were grown either in intermediate media containing Lys-4, Arg-6 (each 1ug/ml) and AHA (0.2 
ul/ml), or in heavy media containing 1ul/ml Lys-6, Arg-10 (each 1ug/ml) and AHA (0.2 ul/ml). 
Supernatant was collected from 2 – 4 million cells cultured in 10 ml of the same medium for 24 h, 
cleared by centrifugation at 4000 RPM for 10 min before analysis by LC-MS/MS. The viability of 
the cells after AHA incorporation was assessed with ViCellar. The passage numbers are p10 for 
CB660, p10 for U5, p14 for CB11130, p40 for G144, p31 for G166 and p30 for G7.  
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Peptide sample preparation 
The cell pellets were homogenized in RapiGest (Waters) followed by reduction of disulphide bonds 
using 100 mM dithiothreitol (DTT), alkylation using 100 mM iodoacetic acid (IAA) and protein 
digestion using sequencing grade modified trypsin (Promega) overnight at 37°C. Peptides were 
stable isotope-labelled via reductive dimethylation, as described in [20]. Peptides were fractionated 
into 12 fractions on Agilent 3100 OFFGEL Fractionator (settings as described by the 
manufacturer).Peptides were acidified, desalted with C18 StageTips (Empore 3M), and 
reconstituted with 4% acetonitrile in 0.1% formic acid. For secretome analysis, 8 ml of each cell 
supernatant was filtered using Amicon Ultra Centrifugal Filters (3-kDa cutoff) to anend volume of 
~250 µL. The proteins in this concentrated media were enriched using the Click-iT Protein 
Enrichment Kit (Invitrogen C10416) and digested with trypsin as described in [19].  
 
Liquid chromatography-tandem MS (LC-MS/MS) 
Peptides were analysed by LC coupled to an LTQ Orbitrap Velos (Thermo Fisher Scientific). 
Reverse phase chromatography was performed with a nanoACQUITY UltraPerformance LC 
system (Waters) fitted with a trapping column (nanoAcquity Symmetry C18, 5 μm, 180 μm x 20 
mm) and an analytical column (nanoAcquity BEH C18, 1.7 μm, 75 μm x 200 mm). The mobile 
phases for LC separation were 0.1% (v/v) formic acid in LC-MS grade water (solvent A) and 0.1% 
(v/v) formic acid in can (solvent B). Peptides were separated at a flow rate of 300 nl/min with a 3 to 
40% solvent B gradient for 145 min for each IEF fraction. The MS1 scan was acquired in the 
Orbitrap from m/z 300 to 1,700. Fragmentation was performed in the LTQ by CID, selecting up to 
15 most intense ions (top15) at an isolation window of 2 Da. 
 
Data processing 
Raw files were processed with MaxQuant [21] version 1.2.0.17 and the Andromeda search engine 
[22] . The MS/MS spectra were searched against the Human UniProt database (downloaded on 
June 21, 2011) containing 69906 forward sequences which was appended to the same number of 
reverse sequences and 265 common contaminants. The precursor mass tolerance was set to 20 
ppm for the first pass and 6 ppm for the 2nd pass. The fragment mass tolerance was 0.5 Da. 
Quantification was done by DimethylLys0 + DimethylNter0 for the light labelling and DimethylLys4 
+ DimethylNter4 for the intermediate labelling. Unique- and razor peptides were used for 
quantification. Cysteine carbamidomethylation and methionine oxidation were set for the fixed 
modification and variable modification, respectively. In case of AHA experiments, methionine was 
replaced with AHA. The minimum peptide length was set to 6 amino acids, the enzyme specificity 
was set to trypsin/P, the maximum allowed miss-cleavage was set to 2, and the false discovery 
rate (FDR) was set to 0.01 for both peptide and protein identifications. Re-quantification and match 
between runs were also performed. The protein identification was reported as a “protein group” if 
no unique peptide sequence to a single database entry was identified. The data were deposited to 
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Chorus (https://chorusproject.org/pages/dashboard.html#/projects/all) under the project title 
'Proteome and secretome characterisation of normal and glioblastoma-derived neural stem cells' 
(project ID 723). After MaxQuant processing, reverse and contaminant proteins and proteins with 
only one peptide identification were discarded. MaxQuant-computed raw protein ratios were 
normalized with median and median absolute deviation (MAD) using the following scheme: 
 
      
 
 
where Xj is the raw protein ratio of protein j.  
 
Differential expression analysis 
To determine differential protein expression we only considered proteins quantified in all the four 
GNS samples, split the data into intensity bins each containing 300 proteins to account for 
dependence of ratio variance on the intensity. Significance for differential protein expression was 
tested for each bin by a moderated t test using the limma R package [23] and correction for 
multiple testing by the Benjamini-Hochberg method with an FDR threshold of 0.05. Subsequently, 
protein groups with expression value less than 2-fold were discarded. Cell line-specific differentially 
expressed protein groups were defined as 1) those that had expression ratios less than 2-fold (up 
or down) in the cell line in question but more than 4-fold in the other three cell lines, or 2) those that 
had expression values more than 4-fold (up or down) in the cell line in question but less than 2-fold 
in the other three cell lines in the reverse expression direction. 
 
Transcriptome data 
The Tag-Seq data of NS and GNS cell lines was obtained from our previous study [24] including 
485 upregulated and 254 down-regulated genes in GNS cells relative to NS cells. The passage 
numbers of the cell lines used in this study were between 10 – 20. 
 
In silico protein functional analysis 
The annotation of “transcription factor/regulator” was retrieved from Panther, MetaCore (GeneGo 
Inc.) and UniProt keywords (http://www.uniprot.org/keywords/). Transcription targets were retrieved 
from MetaCore, and prior association with glioma stem cells, glioma cells and neural stem cells 
was investigated by PubMed literature search. Gene set enrichment analysis (GSEA) of 
differentially expressed proteins were subjected to a Fisher's exact test for the chromosomes,  
Gene Ontology (http://www.geneontology.org/) biological processes (GO.BP),  Panther pathway, 
Reactome Pathway/Complex, WikiPathway, CORUM, and KEGG using all quantified proteins as 
the background and correcting for multiple testing by the Benjamini-Hochberg method. 
Computational prediction of secreted proteins was performed using SignalP 
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(http://www.cbs.dtu.dk/services/SignalP/), and by UniProt including proteins with the keywords 
“Signal”, “Secreted” or “Extracellular space”. If a protein belongs to at least one of these four 
criteria, that protein is considered “predicted to be secreted” otherwise “not predicted to be 
secreted”. Known interactions between ligands and receptors were retrieved from MetaCore. 
Plasma membrane receptors were defined as those having either the UniProt keyword “cell 
membrane” or Panther protein class “receptor” or GO.CC “plasma membrane”. Self-interactions 
were discarded. 
 
Network analysis 
Protein-protein and protein-DNA interactions and their 1st neighbours were retrieved using 
Cytoscape [25] plugin BisoGenet [26] further expanded by CytargetLinker [27] for transcriptional 
interactions from ENCODE and TFe (http://www.cisreg.ca/cgi-bin/tfe/home.pl). From this network, 
all the enriched processes from the GSEA as well as differentially expressed proteins were 
extracted. The resultant subnetwork was then processed with jActiveModule [28] in order to extract 
a subnetwork of low adjusted p-values using the simulated annealing algorithm.Direct interactions 
among the differentially expressed proteins and mRNAs were retrieved from MetaCore. The 
network edges (i.e., interactions) were pruned using the method developed by Crespo et al [29] , 
visualizing the best network configuration using the Cytoscape plugin BiNoM (version 2.5) [25]. 
 
Immunoblotting 
Cells were lysed in 150 mM NaCl, 20 mM Tris-HCl pH 7.5, 0.5% NP-40, 2 mM EDTA, 1 mM NaF 
and protease inhibitors. Primary antibodies used were: Tenascin-C (1:100, Sigma), Galectin-3 
(1:100, abcam), CD9 (1:100, Millipore), and GAPDH (1:1000, GeneTex).  
 
Immunocytochemistry 
Cells were fixed in 4% paraformaldehye (PFA) for 8 min,washed/permeabilised (1× PBS+0.1% 
Triton-X 100) and blocked for 1 h inwash buffer plus 3% goat serum and 1% BSA. Primary 
antibodies were incubated overnight at 4 °C,washed for 2 x 5 min followed by incubation with 
secondary antibodies for 1 h at room temperature. Images were taken using an Olympus IX50 
inverted fluorescent microscope with a DP-50 camera. DAPI was used as a nuclear counterstain. 
Species-specific or Ig-subtype specific goat secondary antibodies were used throughout with either 
Alexa488 or Alexa594 fluorophores (Molecular Probes/Invitrogen). Fluorescence images were 
quantified in ImageJ. The CD9 fluorescence signal was thresholded in order to create a binary 
mask delineating the contours of individual cells. When cells were too close from one another to be 
properly separated, a boundary between the cells was drawn manually. Disconnected areas of the 
binary mask were then labelled with a unique identifier (Analyse Particle plugin) and the mean gray 
level intensity of the CD9 signal was measured for each labeled area.  
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Results 
 
Differential protein expression and secretion between NS and GNS cells  
To reveal the differences in protein expression between NS cells and GNS cells, we performed an 
in-depth proteomics analysis. The experiment was set up such that four individual GNS cell lines 
(G144, G166, G25, G179) [30], covering a diversity of primary GBM subtypes (not IDH1/2 mutant), 
were each compared to a common reference consisting of a pool of four NS cell lines (CB660, 
CB192, CB152 and CTX985) (Figure 1A), thus allowing us to identify proteins that are consistently 
differentially expressed between NS and GNS cells, as well as those that differ between individual 
GNS lines. This required 120 LC-MS/MS runs, quantifying 7476 proteins, of which 6492 were 
quantified in all the samples (Suppl Table T1). The mean protein ratio correlation between 
replicates applying reverse isotope labelling was 0.62 (Figure S1). The mean sample correlation 
coefficient based on protein ratios quantified in all the samples was 0.38 (Figure S2), suggesting 
extensive differences between the GNS cell lines. There were 136, 110, 59 and 79, cell line 
specific differentially expressed proteins in G166, G144, G25 and G179 lines, respectively. The 
differential abundance test between the four GNS cells and the pooled NS sample yielded 465 
differentially expressed proteins (Figure 1B and Suppl Table T1), 447 of which were present in all 
four GNS cell samples (155 were higher in GNS cells; 292 were higher in NS cells). We focused on 
these 447 differentially expressed proteins in the subsequent analyses (Suppl Data set D1). In 
parallel we assessed the secreted proteome for each of three GNS lines (G144, G166 and G7) 
compared to a common reference consisting of the pooled secretome of 3 NS cell lines (CB660, 
U5, and CB11130) (Figure 1A). The mean protein ratio correlation between biological replicates 
was 0.86 (Figure S3) with a mean sample correlation coefficient based on protein ratios quantified 
in all the samples of 0.6 (Figure S4). 1718 proteins were quantified across all the three samples, of 
which 363 were differentially expressed (Suppl Table T1). Among the 389 proteins with predicted 
secretion (see Materials and methods), 138 were differentially expressed (122 up- and 16 down-
regulated). 225 differentially expressed proteins were not predicted to be secreted (135 up and 90 
down) (Suppl Data set D2). 
 The volcano plot of differentially secreted proteins shows that GNS cells tend to secrete 
more proteins than NS cells (Figure 1C). The small overlap of differentially expressed proteins from 
the characterised total proteome and secretome (37 proteins) suggests that our secretome 
experiment was able to capture proteins which were not differentially expressed in the total cell 
experiment, most likely due to differential secretory activity for specific proteins (Figure S5). The 
full details of all quantified proteins from the proteome and secretome experiments are listed in 
Suppl Data sets D1 and D2, respectively. 
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Gene set enrichment analysis (GSEA) captured known chromosomal aberrations and 
putative tumour-associated processes 
The 447 differentially expressed proteins consistently differentially expressed across the four GNS 
cell lines were subjected to GSEA to gain insight in over-represented biological processes (Table 1 
and Suppl Data set D3). At the chromosome level, proteins expressed from chromosomes 7 and 
15 were over-represented, while those from chromosome X were under-represented. This is 
consistent with the known gains of chromosome 7 and loss of 15 in GBMs and GNS cell lines [3, 
24]. Indeed, when plotting protein ratios between NS and GNS cells along all chromosomes, 
protein expression of chromosome 7 was increased, whereas that of chromosome 15 was 
decreased in each of the cell lines (Figure 2A). In addition, Figure 2A shows differential protein 
expression from distinct chromosomal regions in individual cell lines, e.g. increased expression 
from chromosome 19 in G166, and decreased expression from chromosome 10 in G25 suggesting 
additional chromosome aberrations. The under-representation of X could be due to the fact that 
GNS lines contained fewer females than in NS lines. The clear detection of known glioma 
associated karyotype abnormalities from our data gave us confidence in the approach. 
 The over-representation of Gene Ontology Biological Processes “cell differentiation” and 
“neuron differentiation” (Table 1) may relate to tumour-specific abrogation of differentiation 
commitment and mitotic arrest. Enrichment of cell motility-related categories such as regulation of 
cell migration, cell junction organization and gap junction could be explained by the increased cell 
motility and invasive property of GNS cells. In addition, several integrin-related categories were 
enriched, possibly reflecting their known role in the ECM to modulate cellular shape, motility and 
cell cycle progression [31] . Integrin-ECM interactions are also well known to be important 
components of stem cell niches across diverse tissues. Furthermore, interactions between the 
ECM and the actin cytoskeleton commonly take place at focal adhesions. In agreement with this, 
ECM-, focal adhesion- and cytoskeleton related processes were over-represented (Table 1), 
including proteins such as collagens, MAPKs, integrins, SRC and RRAS, suggesting the 
importance of ECM re-organization for tumourigenesis, a property that is apparently maintained 
even in cultured cells. Detection of several notable signalling pathways with previously known roles 
in glioma including ERK1 activation, negative regulation of TGF-beta receptor signalling pathway, 
positive regulation of calcium-mediated signaling, indicates that these pathways remain active in 
vitro and that their disregulation could be associated with tumourigenicity. Endocytosis is known to 
digest ECM components such as Cadherins and its over-representation in our GNS cells may 
suggest an enhanced microvesicle transport of RNA and proteins, which was previously reported 
in glioma cells [32] . The GSEA using CORUM and ReactomeComplex resulted in largely a similar 
result with many integrin- and focal adhesion-related complexes (Suppl Data set D3). Taken 
together, our analyses captured known chromosomal aberrations and many biological pathways 
and processes that could be responsible for GNS malignancy, and identified altered integrin-
mediated signalling as the most notable difference between normal NS and GNS cells. 
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Expression of known glioma stem cell markers between GNS and NS cells 
In our data set we examined expression of proteins that have been defined as glioma stem cell-
associated markers in recent years (Figure 2B and [33, 34] ). We found that LGALS3, LGALS3BP, 
L1CAM and GFAP were consistently over-expressed, while ALDH2 and ITGA6 were under-
expressed in GNS cells (Figure 2B). LGALS3 is an adult astrocyte stem cell marker known to have 
many functions [35] ; L1CAM was shown to partially regulate the DNA damage checkpoint 
response and radio-resistance of glioma stem cells through the activation of the ATM kinase 
pathway [36]. 
 PROM1 (CD133) has been shown to be a marker of glioma cells both in vitro and in vivo 
[37] . Although PROM1 has been used to isolate brain tumour stem cells [4, 38] , it was not 
differentially expressed when compared to the NS cells (also not on the mRNA level [24] ), 
suggesting that this marker may be shared between NS and GNS cells. GFAP is an astrocyte 
marker, but is also expressed by quiescent adult neural stem cells and foetal radial glia in humans 
[3]. Finally, ITGA6 is a receptor for the ECM protein laminin and its mRNA was highly expressed in 
embryonic, neural, and heamatopoietic stem cells [39]. In summary, several known glioma stem 
cell markers were differentially expressed between NS cells and GNS cells. 
 
Differential expression of TFs in NS and GNS cells 
In our data we identified 36 TFs that were consistently differentially expressed in all four GNS cell 
lines compared to NS cells, 19 of which were up-regulated and 17 were down-regulated (Suppl 
Table T2). They include anticipated tumour suppressors (e.g. TP53, YAP1) and cell cycle 
regulators (LZTS1, HMGA2). Eight of these have been implicated in glioma (Suppl Table T2), while 
others have been associated with other cancers. HMGA2 was under-expressed in GNS cells, 
consistent with data at the mRNA level [24] and with its low expression or absence of mRNA in 
glioblastoma tissue in comparison to low-grade gliomas [40] . LZTS1 is known to activate CDK1 by 
physical interaction, however it has not previously been linked to glioma (Suppl Table T2). Finally, 
STAT3 was not among the 447 differentially expressed proteins, yet it was consistently under-
expressed in all the four GNS cell lines (mean log2 ratio -0.98, adjusted p-value 0.03). STAT3 was 
implicated in maintaining the stemness of glioma stem cells [41] , however its down-regulation in 
our GNS compared to NS cells might indicate its role specifically in tumourigenesis, rather than 
stem cell-related properties. 
 
Comparison of proteomics data with transcriptome data in GNS and NS cells 
Since a comparison of differentially expressed mRNAs between GNS and NS cells was previously 
reported [24], we intersected this transcriptome data with our new proteomic data. We identified 34 
gene products showing consistent up- or down-regulation (15 up, 19 down regulated) both at the 
mRNA and protein levels (Figure 2C). The set of up-regulated proteins/mRNAs included the 
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above-mentioned GFAP and LGALS3, and NNMT and CD9. Notably, NNMT was previously 
reported as up-regulated in glioma stem cells in comparison to normal NS cells [14] . CD9 is a 
tetraspanin found in exosomes and has been shown to modulate cell migration and tumour 
metastasis [42] . Among the gene products down-regulated at both protein and transcript levels, 
TAGLN (Transgelin) has been characterised as a tumour suppressor gene in non-brain tissues [43] 
. In contrast, many genes were differentially expressed only at the protein level and therefore could 
not have been detected with transcriptome profling studies. Of note, FOXO3 was up-regulated in 
GNS cells even though mRNA showed no differential expression (mean log2 ratio 0.02, adjusted p-
value 1), and it may therefore undergo post-transcriptional regulation. 
 
Classification of differentially secreted proteins  
We next defined two sets of differentially expressed proteins from the secretome experiment; Set 1 
contains proteins predicted to be secreted and Set 2 contains those not predicted to be secreted 
(see Materials and method for details). Set 2 can be important since many secreted proteins have 
been shown to lack a signal peptide for the classical endoplasmic reticulum (ER)-Golgi pathway, 
and are secreted via unconventional pathways [44] . Indeed, among the 229 proteins in Set 2, 170 
were either predicted to be unconventionally secreted by SecretomeP 2.0 [45] or found in 
exosomes [46]. Proteins in Set 1 and Set 2 were functionally categorized using UniProt keywords 
and keywords that are likely to be related to tumourigenesis (Suppl Figure S6). The top three most 
abundant keywords in Set 1 were "Receptor / membrane protein", "Cell adhesion" and "EGF-like 
domain", whereas those in Set 2 were "Receptor / membrane protein", "Protease / protease 
inhibitor" and "Differentiation". The large number of receptor / membrane proteins suggests that 
many of these proteins are shed to the extracellular space. Additionally, we found total 31 
differentially expressed proteases / protease inhibitors, including serine proteases (SERPINB6 and 
SERPINB8), metalloproteinase-related proteins (ADAM10, TIMP1, TIMP2 and TIMP4) and 
cathepsins (CTSA and CTSD), possibly involved in matrix degradation and tumour cell invasion 
and migration, a well-known feature of highly infiltrative GBM cells [47-51].  
 Growth factors and cytokines constitute another important class of signaling proteins that 
are difficult to capture in total cell proteome. Our secretome data contained 10 differentially 
expressed proteins in this category (CAT, CSF1, GRN, IGFBP4, LTBP4, NOV, PRNP and VEGFA 
(over-expression), IGFBP3 and IGFBP5 (under-expression)), primarily known to promote cell 
proliferation. 26 proteins belonged to the category “Cell adhesion” (Suppl Figure S6) and as such 
may be related to cancer-cell invasion. This group includes proteins with (e.g. L1CAM, MCAN, 
NID2) and without prior association with glioma (e.g. FREM2, LGALS3BP, FLRT3). Taken 
together, our secretome analysis provides a valuable complement to the data on the cellular 
proteome, identifying many extracellular proteins with an enzymatic or signaling function. Several 
of these are known to play a role in glioma, but this also includes several novel candidates that 
may be investigated in future functional studies. 
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Interaction between differentially expressed secreted proteins and receptors identified 
potential GNS markers 
Next we explored known interactions between differentially expressed ligands (in the secretome) 
and differentially expressed plasma membrane receptors (in the total proteome), reasoning that 
this combined data may identify specific ligand-receptor pairs associated with GNS cell properties. 
Of the147 interactions (Suppl Data set D4), we particularly focused on pairs where both ligand and 
receptor expression changed in the same direction, as they are likely to be signatures of 
downstream expression changes. We identified 37 such pairs, 26 and 11 of which were up-
regulated and down-regulated in GNS cells, respectively (Table 2). Among these, some play a 
prominent role in tumourigenesis, such as "cell adhesion" (ADAM10-CD9, LGALS3BP-CD9, 
ADAM10-L1CAM, L1CAM-NCAM1) and "immune system process" (PRNP-C1QBP, ADAM10-
L1CAM, CSF1-MYD88, PRNP-L1CAM, CANX-L1CAM, TXN-MYD88, CANX-NDRG1 and B2M-
TFRC). Several of these proteins have been highlighted above, and they may now be positioned 
more firmly in the context of distinct pathways that are specific for GNS cells. 
 
Molecular interaction networks show proteins central to the difference between NS cells 
and GNS cells 
In order to find which proteins are collectively representing the differences between GNS cells and 
NS cells in the context of molecular networks, we used Cytoscape plugins, BisoGenet and 
CytargetLinker to retrieve known protein-protein and protein-DNA interactions based on 
differentially expressed proteins from both total proteome and secretome experiments and all 
proteins in the enriched processes from the GSEA (Table 1). Then, the sub-network of low 
adjusted p-values was inferred using jActiveModule, resulting in a network of 276 proteins with 539 
interactions (Figure 3A). This unbiased approach recapitulated the differentially expressed 
proteins, and proteins from the enriched processes (integrins, signalling, adhesion molecules, 
cytoskeltal proteins). On top of those, the network contained 12 proteins with >50 network degrees 
(Suppl Table T3), suggesting that these are important in mediating interactions critical to the 
differences between NS cells and GNS cells. Indeed, all of them have been previously implicated 
in glioma and cellular proliferation (e.g. BRCA1, BCL3, SP1, GSK3B, PBX3, SMARCB1). Since 
expression of many of these 12 proteins did not change significantly, this provides a 
complementary approach to identifying biologically important proteins.  
 Additionally, to infer a gene regulatory network that could underlie the difference between 
GNS and NS cells, differentially expressed proteins and mRNAs from [24] were also analysed 
using the previously proposed method [29]. This identified a gene regulatory network core (Figure 
3B) that could best explain the differential expression between GNS cells and NS cells. 
Reassuringly, this network included several well-known tumour-associated proteins such as 
PDGFRA, EGFR, TP53, and MYC, which are the major genetic drivers of tumourigenesis in 
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glioblastoma, as well as CD9 and TNC (tenascin C).TNC is an ECM glycoprotein that is abundantly 
expressed in foetal NS cells and vanishes as the organism matures and is absent in normal adult 
brains [52] but re-expressed upon injury or neoplasia [53, 54]. In addition, cytotoxic-antibodies 
against TNC have been under clinical trials [55]. This agrees with our data where TNC shows 
elevated expression in GNS cells compared to NS cells.  
 
Immunocytochemistry and immunoblotting confirm CD9 enrichment in GNS cells compared 
to NS cells 
Our bioinformatics analyses aimed to catalogue the differences between GNS cells and NS cells in 
an unbiased manner. We next shortlisted genes that appeared at least twice in different analyses. 
We particularly focused on cell-surface proteins since they are potential mediators of signalling or 
protein secretion, and that may be accessible for cell sorting and future therapeutic targets. From 
these considerations, four candidates emerged (TNC, THY1, LGALS3 and CD9 (Figure 4A). CD9 
is of particular interest given its recent identification as a potential endogenous NS cell marker in 
mice [15]. Western immunoblotting was performed for TNC, LGALS3, and CD9 using a larger set 
of lines (Figure 4B). We found no clear differential expression for TNC with the antibodies used, 
and LGALS3 failed to be confirmed as consistently enriched in GNS cells across a larger panel of 
lines. However, by both immunocytochemistry and western immunoblotting we were able to 
confirm that CD9 is consistently over-expressed in GNS cells, compared to  NS cells (Figure 4C, 
D) demonstrating that CD9 can distinguish these cell types. Finally, apatient survival analysis was 
performed over large cohorts of primary GBM tumours usingthe Rembrandt database 
(http://www.betastasis.com/glioma/rembrandt/). This revealed a significant negative correlation 
between the CD9 expression levels and overall patient survival (Figure 4E),suggesting that it may 
have value as a GNS-specific marker. 
 
 
Discussion  
 
It has been recognized that only a subset of cells within GBM is able to reconstitute a tumour and 
is therefore responsible for driving tumour development in vivo [2-4]. These stem cell-like cells (i.e. 
CSCs) share similar functional properties with normal stem cells including the abilities to self-renew 
and differentiate. As cells regulate themselves and nearby cells through the niche by secreting 
auto/paracrine cues, not only intracellular proteins but also proteins secreted from these cells are 
likely to contribute to the difference between malignant and normal stem cells. To reveal such 
differences in protein expression between untransformed, karyotypically normal foetal NS cells and 
malignant NS cells derived from adult gliomas (GNS cells), we have performed mass spectrometric 
analyses of both total cell proteomes and secreted proteomes. We used cells expanded in 
adherent monolayer culture, which provides a more uniform culture environment with reduced 
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differentiation and apoptosis that accompany suspension cultures [3]. The direct comparison 
between NS and GNS cells removes those set of genes that are shared stem cell-related 
properties present in both cell types, enabling us to focus on protein repertoires distinguishing non-
malignant NS cells from highly malignant GNS cells. Comparisons between normal stem cells and 
CSCs is an important research question, as this knowledge might be useful for specifically 
targeting CSCs, while minimizing the effect on the normal counterparts [8]. 
 The result showed that, as anticipate there are striking differences between each patient 
GNS cell line, mirroring the distinct variants of the human disease. However, by focusing on 
proteins differentially expressed across all GNS cell lines tested, we aimed to derive ‘core’ 
malignant properties shared across different individuals and across the genetic diversity.At the 
same time, this would equalize differences between cell lines arising from potential spatial or 
temporal variation of the collected tissues or cell of origin. The generated proteomics and 
secretome data and our previous transcriptome data comparing GNS cells with NS cells [24] 
providing a compendium of differentially expressed proteins; this was used to perform a multi-
layered bioinformatic analysis to define most significantly utilized tumour-enriched pathways. 
Several patterns emerged from this analysis that partly confirmed existing literature, while 
extending the panel of GNS-specific proteins with novel candidate markers and functional 
regulators (Figure 5). For instance, among the known NS cell and glioma stem cell markers, 
LGALS3, LGALS3BP, L1CAM, GFAP were more highly expressed in GNS cells, while expression 
of ITGA6 and ALDH2 was reduced. These markers are expressed by quiescent niche-dependent 
adult stem cells, and maybe highlight the ability of glioma genetic drivers to impose aberrant 
proliferation of both the quiescent cells (type B-like cells) as well as the activated rapidly dividing 
stem and progenitors (type C cells) [56]. Additionally, 36 transcription factors/regulators were 
differentially expressed, 9 of which (FOXO3, TP53, IFI16, NFIC, PURA, YAP1, HMGA2 and 
PRKCB) have been previously implicated in glioma, whereas the other 27 are unreported.  
 The GSEA of the 447 differentially expressed proteins showed several tumour-associated 
processes, including those related to ECM interactions, focal adhesion, cell motility, structural 
organization and cell signalling. These findings suggest that aggressive tumour initiation and 
infiltration of GNS cells is explained by these sets of proteins being expressed. The clear difference 
in regulation of ECM could also support the notion that a tumour-specific niche is created by 
tumours with increases in adult quiescent stem cell markers such as LGALS3 and GFAP. This 
would enable for self-renewal to be sustainedby the GNS cells outside of the endogenous SVZ 
niche – likely protecting the GBM stem cell from pro-differentiation cues. 
 In our secretome analysis a striking observation was that the majority of differentially 
expressed proteins were preferentially secreted by GNS cells (122 out of 138). This trend was also 
observed in the comparison between cancer and normal cells in our previous work [13]. Many of 
these differentially secreted proteins belong to the tumour-related functionalities such as cell 
adhesion, protease / protease inhibitor and growth factor / cytokine / mitogen. The fact that 
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proteases and growth factors were abundant in the differentially expressed secretome proteins but 
not in the differentially expressed proteins in the total cell experiment indicates the importance of 
analysing the extracellular environment to identify proteins with a potential role in shaping the 
tumour micro-environment. 
 Beyond changes in protein expression levels we also considered protein connectivity in 
interaction networks to estimate their potential impact on associated cellular processes, reasoning 
that a change in the expression of proteins that formed the regulatory core have a high influence 
on the cellular phenotypes. This revealed, for example, several well-known players in regulating 
processes related to cell proliferation, in particular in cancer cells (BRCA1,BCL3, GSK3B, PBX3, 
SMARCB1). Furthermore, by combining these bioinformatics approaches with the differentially 
abundant receptor-ligand pairs and our previous transcriptome data, we identified potential GNS 
markers that could be distinguished from normal NS counterparts, including CD9. Western blot and 
immunofluorescence analysis confirmed that CD9 was significantly highly expressed in the GNS 
cells in comparison to the NS cells. CD9, a transmembrane protein of the tetraspanin family, has 
been variedly associated with pro- or anti-metastatic properties depending on cellular context and 
tumor entity, determined in part by interactions with other membrane-embedded signaling proteins 
(reviewed in [57]). Importantly, recent evidence has indicated that CD9 itself supports maintenance 
of glioblastoma stem cells [58]. Our data demonstrating that CD9 is consistently higher expressed 
in GNS cells compared to NS cells provides further evidence for the functional relevance and 
potential practical utility of CD9, such as sorting of GNS cells from NS cells, or as a GNS-specific 
target of drugs and antibodies. Interestingly, our secretome analysis identified 3 CD9-ligands 
(ADAM10, LGALS3BP and PTGFRN, Table 2), which were all up-regulated, and each of which has 
been linked to metastasis [59-61], including in glioma and glioblastoma. This provides one example 
how quantitative proteome and secretome analysis offers a powerful means to investigate protein 
expression as well as the proteins involved in extracellular signaling and that crucially determine 
downstream effects. 
 Altogether our proteomics data enabled us to globally characterize molecular signatures 
that are differentially active/inactive between GBM stem cells and normal neural stem cells, and 
will be a valuable resource for future glioma studies. 
 
 
Data availability: all mass spectrometry data associated with this study can be downloaded from 
Chorus (https://chorusproject.org/pages/dashboard.html#/projects/all) under the project title 
'Proteome and secretome characterisation of normal and glioblastoma-derived neural stem cells' 
(project ID 723). 
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Legends of Tables and Figures 
 
 
Table 1. Enriched GSEA categories among differentially expressed proteins between GNS 
and NS cells. 
(A) chromosomes, (B) Gene Ontology Biological Process (GO.BP), (C) Panther Pathway, (D) 
Reactome Pathway, (E) WikiPathway and (F) KEGG. Annotation: total number of genes in category, 
differentially expressed genes: number of differentially expressed (DE) genes, padj: Fisher's exact 
test p-value adjusted with Benjamini Hochberg correction.  
 
 
Table 2.   Interactions between differentially expressed ligands and receptors.  
Interactions between ligands and receptors that were consistently up- or down-regulated in the 
secretome and total proteome, respectively, as retrieved from MetaCore. Each interaction was 
manually validated from references in the literature. 
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NS cell lines GNS cell lines
digest & label (heavy)
digest & 
label (light)
digest & 
label (light)
digest & 
label (light)
digest & 
label (light)
CB660
Pooled NS
CB192
CB152
CTX985
G144
G166
G179
G25
pooled NS
vs. G144
pooled NS
vs. G166
pooled NS
vs. G179
pooled NS
vs. G25
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Figure 1. Quantification of GNS total cell proteome and secreted proteome. 
(A) Overall experimental design for the analyses of cellular proteomes and secretomes comparing 
GNS to NS cells. (B) Volcano plot of protein ratios (GNS/NS) for total cell experiment. (C) Volcano 
plot of protein ratios (GNS/NS) for secretome experiment. Red and blue dots in panel B and C 
indicate proteins that are up- or downregulated, respectively, at least 2-fold and with statistical 
significance (adj-p value <= 0.05). 
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Figure 2. Differential protein expression Heatmap of protein expressions from different 
criteria. 
(A) Protein ratios as a function of chromosomal locations in each of four GNS cell lines relative to a 
pool of NS cell lines.The top trace displays the average ratio of all four GNS cell line. Solid black 
line is a moving average of 10 ratios. Chromosome number is indicated on top. (B) Heatmap of 
known NS and/or GNS marker expression. Asterisk indicates differential expression with statistical 
significance. Proteins indicated with ** were consistently differentially regulated across all 4 cell 
lines. (C) Heatmap of proteins that were up- and down regulated on both protein and mRNA levels. 
The colour key is the same as B. The last column (mRNA) is mean  log2 fold-change(GNS/NS) of 
mRNA expressions in cell lines used in [24].   
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Figure 3. Network analysis of differentially expressed proteins. 
(A) A network of 276 proteins created with Cytoscape plugin jActiveModule with adjusted p-value as 
input parameter. Protein-protein, protein-DNA and transcriptional interactions were retrieved from 
various databases using Cytoscape plugins BisoGenet and CytargetLinker. Each node represents a 
protein, while the shape of the node indicates if it originates from total proteome (circles) or 
secretome data (diamonds). Nodes were colour-coded by negative fold-change (blue) to positive 
fold-change (red) in GNS cells. Node size indicates the degree (number of connections). For clarity, 
gene symbols are shown only for those with >50 degrees. (B) A gene regulatory network inferred 
from differentially expressed proteins and mRNAs. 
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Figure 4. Validation of candidate markers in GNS cells.  
(A) Inclusion criteria for proteins in experimental follow experiments. (B) Western blot analysis of 
CD9, LGALS3and TNC across 5 GNS and 5 NS cell lines showing consistent increased expression 
of CD9 in GNS cells. (C). Immunocytochemistry of CD9 (green) and nuclei (DAPI, blue) across 5 
GNS and 5 NS cell lines. (D) Quantification of CD9 expression in GNS and NS cells derived from 
panel C.(E) Glioma patient survival analysis of CD9 using the Rembrandt database. 
 
Figure 5.Model summarizing differentially expressed proteins and enriched processes. 
The displayed proteins and processes summarize the combined results of GSEA projected on 
cellular localization. Arrows pointing upwards and downwards indicate up-regulated and down-
regulated proteins in GNS cells compared to NS cells. 
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Table 1 
Gene set feature 
Annotated  
genes DE genes padj 
A. Chromosome     
15 225 27 0.011 
7 366 36 0.035 
X 269 6 0.043 
B. GO.BP       
cell differentiation 1001 97 0.000 
endocytosis 176 29 0.000 
neuron differentiation 444 53 0.000 
integrin-mediated signaling pathway 31 9 0.004 
NAD metabolic process 18 7 0.004 
blood vessel development 187 24 0.011 
regulation of cell migration 146 20 0.015 
response to metal ion 108 16 0.019 
cell-cell adhesion mediated by integrin 7 4 0.020 
negative regulation of transforming growth factor 
beta receptor signaling pathway 17 5 0.040 
positive regulation of calcium-mediated signaling 5 3 0.045 
extracellular matrix organization 65 10 0.049 
C. Panther pathway     
Integrin signalling pathway 113 26 0.000 
Cytoskeletal regulation by Rho GTPase 45 9 0.023 
D. Reactome pathway       
Cell-extracellular matrix interactions 11 10 0.000 
Cell junction organization 34 13 0.000 
L1CAM interactions 70 16 0.000 
Regulation of cytoskeletal remodeling and cell 
spreading by IPP complex components 5 5 0.002 
Response to elevated platelet cytosolic Ca2+ 38 10 0.003 
Localization of the PINCH-ILK-PARVIN complex to 
focal adhesions 4 3 0.004 
Platelet activation, signaling and aggregation 101 16 0.008 
NCAM signaling for neurite out-growth 35 9 0.009 
Integrin cell surface interactions 45 10 0.009 
c-src mediated regulation of Cx43 function and 
closure of gap junctions 3 3 0.023 
ERK1 activation 3 3 0.023 
Microtubule-dependent trafficking of connexons 
from Golgi to the plasma membrane 8 4 0.028 
E. Wikipathway       
Focal Adhesion 117 18 0.006 
Integrin-mediated cell adhesion 70 12 0.017 
Regulation of Actin Cytoskeleton 92 14 0.020 
Signaling of Hepatocyte Growth Factor Receptor 27 7 0.020 
F. KEGG    
Focal adhesion 122 24 0.000 
Regulation of actin cytoskeleton 123 24 0.000 
Gap junction 45 12 0.000 
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